Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
149.36
+5.74 (4.00%)
At close: Aug 13, 2025, 4:00 PM
149.34
-0.02 (-0.01%)
After-hours: Aug 13, 2025, 5:33 PM EDT
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Krystal Biotech stock ranges from a low of $166 to a high of $245. The average analyst price target of $205.27 forecasts a 37.43% increase in the stock price over the next year.
Price Target: $205.27 (+37.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $176 → $166 | Hold | Maintains | $176 → $166 | +11.14% | Aug 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $219 | Strong Buy | Maintains | $219 | +46.63% | Aug 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $219 | Strong Buy | Maintains | $219 | +46.63% | Jul 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 | Strong Buy | Reiterates | $240 | +60.69% | Jul 25, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $193 → $192 | Strong Buy | Maintains | $193 → $192 | +28.55% | Jul 22, 2025 |
Financial Forecast
Revenue This Year
407.02M
from 290.52M
Increased by 40.10%
Revenue Next Year
609.42M
from 407.02M
Increased by 49.73%
EPS This Year
5.75
from 3.00
Increased by 91.79%
EPS Next Year
9.36
from 5.75
Increased by 62.72%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 432.0M | 742.1M | 1.1B | ||
| Avg | 407.0M | 609.4M | 882.8M | ||
| Low | 361.5M | 412.4M | 696.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 48.7% | 82.3% | 87.6% | ||
| Avg | 40.1% | 49.7% | 44.9% | ||
| Low | 24.4% | 1.3% | 14.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.39 | 14.88 | 23.91 | ||
| Avg | 5.75 | 9.36 | 13.71 | ||
| Low | 3.45 | 5.95 | 8.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 179.7% | 158.6% | 155.4% | ||
| Avg | 91.8% | 62.7% | 46.5% | ||
| Low | 15.0% | 3.4% | -13.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.